First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Humana Inc. (HUM): the developments shaping its investment case

    Follow the evidence affecting Humana Inc.'s margins. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Humana Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-05 · 2 reports
    UnitedHealth Medical Care Ratio Drops to 85.3% as 2026 EPS Consensus Rises 21%
    Channel: Second-order effect: Similar to ELV, HUM, as another large health insurer, could see positive sentiment and potentially benefit from broader favorable medical cost trends, improving its own profitability outlook.
    Bullish· 1-3m
    2026-09-12
    Centene improves Medicare health benefit ratio to 89.5% amid footprint reset
    Channel: Sector-wide sentiment improvement due to positive operational signals from a peer, suggesting broader industry trends.
    Bullish· 1-3m
    2026-09-12
    Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%
    Channel: As a major Medicare Advantage provider, Humana is directly exposed to the 'ongoing margin repricing across the managed care complex' and regulatory changes affecting MLR and profitability.
    watch· 1-3m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-07-09marginBearishIdentified by HHS OIG for high denial rates in post-acute prior authorization, increasing regulatory risk for MA-heavy insurers.

    Event impact log

    26 events mapped to HUM since 2026-09-05. Evidence through 2026-09-18.

    DateEventChannelDirectionHorizonImpact
    2026-09-18Centene Posts $2.51 Q2 EPS as Medical Cost Turnaround Offsets 8%-9% Medicaid ShrinkageIndustry-wide trends in medical utilization and government program enrollment, particularly Medicare Advantage.watch3-12m0.40
    2026-09-18Centene posts $2.51 Q2 EPS as Medicaid rolls shrink 8%-9% in 2026Industry-wide trends in government-sponsored health programs.watch3-12m0.40
    2026-09-18Centene posts Q2 adjusted EPS of $2.51 amid 8%-9% projected Medicaid roll-offIndirect read-through on broader Medicaid market trends and competitive landscape.watch3-12m0.30
    2026-09-18Centene Delivers $2.51 Q2 EPS as Commercial Margins Offset 9% Medicaid DeclineIndustry-wide trend confirmation (Medicaid decline, Medicare/commercial market strength).watch1-3m0.30
    2026-09-18Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 declineSecond-order effect; industry-wide Medicaid enrollment trends could impact HUM's Medicaid segment, though less dominant than Medicare.Bearish3-12m0.30
    2026-09-18Centene Delivers Q2 Adjusted EPS of $2.51, Projects 8%-9% Medicaid DropIndustry-wide trends in government-sponsored health plans (Medicaid, Medicare Advantage) and competitive landscape.watch3-12m0.40
    2026-09-18Centene posts Q2 EPS turnaround to $2.51 as Medicaid rolls off 8% to 9%Industry-wide trends in government healthcare programs, particularly Medicaid and Medicare.watch3-12m0.30
    2026-09-16Oscar Health, Inc. Raises Full Year 2026 Earnings GuidancePotential competitive pressure or industry trend validation. As a major health insurer, OSCR's improved MLR could signal broader industry trends in cost management or competitive dynamics.watch3-12m0.20
    2026-09-16Centene Corporation Reaffirms Full Year 2026 EPS GuidanceIndirect read-through on the broader managed care sector's stability and outlook, as Centene is a significant player.watch1-3m0.30
    2026-09-14Centene Restructures Medicare Advantage Footprint to Target 2027 Margin BreakevenIncreased competition in the Medicare Advantage market, especially for dual-eligible members, and potential for sector-wide margin pressure/expectations.mixed3-12m0.40
    2026-09-13Centene Improves Medicare HBR to 89.5% via Footprint SimplificationIndirect competitive pressure and sector-wide HBR expectations, particularly given Humana's significant exposure to Medicare Advantage.mixed3-12m0.40
    2026-09-13Centene Targets 2027 Medicare Advantage Breakeven as Health Benefit Ratio Hits 89.5%Indirect competitive pressure and potential industry-wide implications for Medicare Advantage profitability and strategy.mixed3-12m0.30
    2026-09-13Centene Targets Medicare Advantage Breakeven After Q2 Benefit Ratio Hits 89.5%Competitive landscape and industry-wide utilization trends in Medicare Advantage.mixed1-3m0.40
    2026-09-13Centene Restructures Medicare Advantage Footprint as Q2 Health Benefits Ratio Reaches 89.5%Indirect competitive pressure and industry-wide trends in Medicare Advantage.mixed3-12m0.30
    2026-09-12Centene Streamlines Medicare Advantage Footprint with Q2 Ratio at 89.5%Indirect competitive pressure and potential for industry-wide adjustments in Medicare Advantage strategy.mixed3-12m0.40
    2026-09-12Centene Medicare benefits ratio recovers to 89.5% aiming for 2027 breakevenIncreased competitive pressure in the Medicare Advantage market, potentially leading to pricing or benefit adjustments to maintain market share, offset by potential for overall market growth.mixed3-12m0.40
    2026-09-12Centene Medicare Health Benefits Ratio Improves to 89.5% in Managed Care OverhaulIndirect competitive pressure and industry benchmark setting. As a significant Medicare Advantage player, HUM's performance is often viewed in context of peers.mixed1-3m0.30
    2026-09-12Centene Medicare health benefits ratio improves to 89.5% in Q2 2026Indirect competitive pressure and industry-wide profitability expectations. Humana has a significant focus on Medicare Advantage.mixed3-12m0.30
    2026-09-12Centene improves Medicare health benefit ratio to 89.5% amid footprint resetSector-wide sentiment improvement due to positive operational signals from a peer, suggesting broader industry trends.Bullish1-3m0.60
    2026-09-12Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%As a major Medicare Advantage provider, Humana is directly exposed to the 'ongoing margin repricing across the managed care complex' and regulatory changes affecting MLR and profitability.watch1-3m0.60
    2026-09-12Centene Lowers Medicare Advantage Benefit Ratio to 89.5% in Q2Similar to UNH, as a major Medicare Advantage provider, Humana's performance is sensitive to industry-wide trends and competitor's operational improvements.mixed1-3m0.40
    2026-09-12Centene simplifies Medicare Advantage book as Q2 benefit ratio reaches 89.5%Competitive landscape shifts and potential industry-wide implications for Medicare Advantage profitability.mixed3-12m0.30
    2026-09-12Centene Medicare Advantage HBR Improves to 89.5% in Q2Indirect competitive pressure and industry-wide operational benchmarks. Humana has a significant focus on Medicare Advantage.mixed3-12m0.40
    2026-09-12Centene trims Medicare health benefits ratio to 89.5% aiming for 2027 breakevenIncreased competitive pressure in the Medicare Advantage market from a re-focused Centene, potentially impacting market share or pricing power for other pure-play MA providers.mixed3-12m0.50
    2026-09-05UnitedHealth Medical Care Ratio Drops to 85.3% as 2026 EPS Consensus Rises 21%Second-order effect: Similar to ELV, HUM, as another large health insurer, could see positive sentiment and potentially benefit from broader favorable medical cost trends, improving its own profitability outlook.Bullish1-3m0.50
    2026-09-05UnitedHealth Medical Care Ratio Drops to 85.3%, Lifting 2026 EPS Consensus by 21%Sector-wide positive sentiment and potential read-through for other managed care organizations if UNH's cost management reflects broader industry trends or effective strategies.Bullish1-3m0.60

    Continue this research

    Build your Humana Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the HUM entity page →

    Research Humana Inc. · $399/mo